Iqvia Stock Price, News & Analysis (NYSE:IQV)

Iqvia trades on the New York Stock Exchange (NYSE) under the ticker symbol "IQV."

Iqvia Holdings Inc (NYSE:IQV) issued its quarterly earnings results on Wednesday, July, 24th. The medical research company reported $1.39 earnings per share for the quarter, beating analysts' consensus estimates of $1.38 by $0.01. The medical research company earned $2.74 billion during the quarter, compared to the consensus estimate of $2.70 billion. Iqvia had a net margin of 2.31% and a return on equity of 15.95%. The business's revenue was up 6.7% on a year-over-year basis. During the same period in the prior year, the firm earned $1.29 EPS. View Iqvia's Earnings History.

Iqvia is scheduled to release their next quarterly earnings announcement on Monday, October 28th 2019. View Earnings Estimates for Iqvia.

Iqvia updated its FY19 earnings guidance on Wednesday, July, 24th. The company provided EPS guidance of $6.25-6.45 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.33. The company issued revenue guidance of $11.00-1.15 billion, compared to the consensus revenue estimate of $11.02 billion.

18 analysts have issued twelve-month target prices for Iqvia's shares. Their predictions range from $136.38 to $180.00. On average, they anticipate Iqvia's share price to reach $164.49 in the next twelve months. This suggests a possible upside of 14.1% from the stock's current price. View Analyst Price Targets for Iqvia.

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iqvia in the last year. There are currently 2 hold ratings, 15 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iqvia.

News headlines about IQV stock have trended neutral on Friday, according to InfoTrie. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Iqvia earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned media coverage about the medical research company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Iqvia.

Iqvia saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 4,630,000 shares, an increase of 42.9% from the August 30th total of 3,240,000 shares. Based on an average daily trading volume, of 1,240,000 shares, the short-interest ratio is presently 3.7 days. Approximately 2.6% of the shares of the stock are sold short. View Iqvia's Current Options Chain.

Some companies that are related to Iqvia include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Charles River Laboratories Intl. (CRL), PRA Health Sciences (PRAH), Syneos Health (SYNH), Exelixis (EXEL), BTG (BTGGF), Medpace (MEDP), National Research (NRC), Intrexon (XON), Auxly Cannabis Group (CBWTF), STARPHARMA HOLD/S (SPHRY), Sorrento Therapeutics (SRNE) and Eloxx Pharmaceuticals (ELOX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Iqvia investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Allergan (AGN), Micron Technology (MU), Workday (WDAY), NIC (EGOV) and Zoetis (ZTS).

Iqvia's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Artemis Investment Management LLP (0.14%), Robeco Institutional Asset Management B.V. (0.11%), Envestnet Asset Management Inc. (0.10%), Howard Capital Management (0.06%), DNB Asset Management AS (0.06%) and State of Alaska Department of Revenue (0.04%). Company insiders that own Iqvia stock include Ari Bousbib, Canada Pension Plan Investment, Cpp Investment Board Private H, Group Holdings (Sbs) Advis Tpg, Jack M Greenberg, James H Erlinger III, John Connaughton, John G Danhakl, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Robert Parks, Ronald A Rittenmeyer and W Richard Staub. View Institutional Ownership Trends for Iqvia.

IQV stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Robeco Institutional Asset Management B.V., Artemis Investment Management LLP, CIBC Private Wealth Group LLC, Gateway Investment Advisers LLC, Enlightenment Research LLC, Howard Capital Management and Three Peaks Capital Management LLC. Company insiders that have sold Iqvia company stock in the last year include Ari Bousbib, Canada Pension Plan Investment, Group Holdings (Sbs) Advis Tpg, Kevin C Knightly, Michael J Evanisko, Michael R Mcdonnell, Ronald A Rittenmeyer and W Richard Staub. View Insider Buying and Selling for Iqvia.

IQV stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Envestnet Asset Management Inc., Meeder Asset Management Inc., Pacer Advisors Inc., Sumitomo Mitsui DS Asset Management Company Ltd, First Hawaiian Bank, Commerzbank Aktiengesellschaft FI and Advisor Partners LLC. View Insider Buying and Selling for Iqvia.

Shares of IQV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IQV stock can currently be purchased for approximately $144.19.

Iqvia has a market capitalization of $28.25 billion and generates $10.41 billion in revenue each year. The medical research company earns $259 million in net income (profit) each year or $5.12 on an earnings per share basis. Iqvia employs 58,000 workers across the globe.View Additional Information About Iqvia.

The official website for Iqvia is http://www.iqvia.com/.

Iqvia's mailing address is 4820 EMPEROR BLVD, DURHAM NC, 27703. The medical research company can be reached via phone at 919-998-2000 or via email at [email protected]